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Abstract
We describe a patient with human immunodeficiency virus 
type-1 (HIV) infection and alveolar echinococcosis (AE) with 
a focus on two messages.
Despite being severely immunocompromised over years the 
patient exhibited a long-term asymptomatic course of AE. 
This is in clear contrast to reports describing accelerated 
courses of AE in immunocompromised patients. 
The patient had therapeutic mebendazole drug levels with 
only 1/10 of the normal drug dose. He was co-treated 
with protease inhibitors for his HIV infection. These drugs 
are known as strong inhibitors of cytochrome P450 3A4 
(CYP3A4)-dependent metabolism. We speculate that benzi-
midazoles and protease inhibitors interfere at the CYP3A4-
level.
The first report of co-infection of HIV and accelerated AE 
was in a young girl with an extremely low CD4 cell count and 
an abrogated lymphoproliferative responsiveness to parasite 
antigen stimulation. Since the CD4 cell count in our patient 
remained in the range of 27–150 cells/µl, we speculate 
that there was a critical threshold of immunosupression for  
constraining AE. Initial treatment with albendazole for AE 
added to the current highly active antiretroviral treatment 
(HAART), and suppressive toxoplasmosis therapy became 
complicated by pancytopenia. After full recovery of the bone 
marrow, mebendazole was introduced with a new HAART 
and the previously prescribed toxoplasmosis maintenance 
therapy. Surprisingly, efficient mebendazole levels were 
achieved with an uncommonly low dose. These observations 
suggest that the benzimidazoles, albendazole and meben-
dazole, may interact with protease inhibitors, which are 
known for their strong inhibition of the CYP3A4.
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Introduction
Alveolar echinococcosis (AE) is caused by the fox tape-
worm Echinococcus multilocularis (EM). Red foxes, and 
to a lesser extent domestic dogs and cats are the definitive 
natural hosts for EM, permissive to the whole replication 
cycle [1]. Man, infected by fecal-oral transmission, acts 
as an accidental intermediate host. The replication cycle 
cannot be completed and thus, the infection is not conta-
gious. The incubation period is 5–15 years from infection 
to the development of clinical symptoms [2]. In about 88% 
of cases AE remains restricted to the liver and adjacent 
organs. In advanced stages it may disseminate to other or-
gans such as lungs, kidneys, the central nervous system, or 
other sites. Clinical symptoms like unspecific abdominal 
pain and jaundice usually arise from the tumor-like, inva-
sive growth of metacestodes in the liver. Lethality of natu-
ral AE reaches 94–100% within 10–15 years after diagnosis 
in untreated or inadequately treated human patients [3]. 
Nowadays, the lethality rate is much lower due to diagno-
sis of smaller AE lesions at an earlier stage and improved 
treatment strategies combining surgery and chemotherapy 
with benzimidazoles [4].
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The immunopathogenesis is still poorly understood. 
Case reports of a 6-year-old girl and several liver trans-
plant recipients suggest rapid disease progression in im-
munocompromised patients [5–7]. Mice treated with cyclo-
sporin A to induce experimental immunodeficiency and T 
cell-deficient athymic nude mice both showed accelerated 
AE [8,  9] when compared to immunocompetent wild-type 
animals. Data from other mouse experiments also pointed 
to a key role of the T helper type-1 responses [10]. 
As outlined above, immunosuppression is suggested to 
be a poor prognostic factor for AE. In contrast, we present 
a case of an HIV-infected male patient with a strikingly 
long asymptomatic course of AE while being severely im-
munosuppressed.
Case Report
In this 40-year-old male patient, HIV infection was diagnosed 
in 1988 at the age of 26 years. In 1994 he suffered from a Pneu-
mocystis jiroveci (formerly Pneumocystis carinii) pneumonia and 
disseminated tuberculosis, and in 1996 from cerebral toxoplas-
mosis. In the same year, the patient was started on antiretrovi-
ral therapy (HAART) with zidovudine (300 mg bid), lamivudine 
(150 mg bid), and ritonavir (600 mg bid). Therapy led to the com-
plete suppression of HIV RNA within 11 months, whereas recov-
ery of the CD4+ T cells was slow and their count remained in the 
range of 27 to 156 cells/µl over the next years (Figure 1A). In Sep-
tember 2001, HAART was discontinued because it was implicated 
in causing parotis enlargement. In November 2001, the patient suf-
fered from severe bacterial pleuropneumonia with  Streptococcus 
oralis. The CD4+ T cells dropped to 28 cells/µl in the context of 
this acute event. HAART was reinitiated with zidovudine (300 
mg bid), lamivudine (150 mg bid) and nelfinavir (1,250 mg bid). In 
February 2002, a CT scan was performed because of dull percussion 
on the right side of the back, revealing pleural thickening and an 
irregularly shaped tumor (10.5 x 8 x 9 cm) in the liver with central 
calcifications. This tumor compressed the right portal vein and the 
middle hepatic vein as shown 3 months later (Figure 2B). Based on 
this CT morphology, AE was suspected. Serology including EGHF-
ELISA, Em2-ELISA (affinity purified EM Em2antigen) and EM-
II/3-10-ELISA (recombinant cytovillin-like protein of EM) were 
all positive confirming the diagnosis of AE [11]. The patient did 
not have pets but he had the habit of collecting green onions from 
forests in a region of known AE infected foxes. A lymphocyte pro-
liferation assay, performed as previously described [12], provided 
a positive response as shown by a stimulation index of 9.1 (indices 
> 4.0 are considered positive). Radical surgery was not possible 
because of the location of the tumor and the patient was started 
on chemotherapy with albendazole (400 mg bid). Within 2 weeks 
after the initiation of antihelmintic therapy, marked pancytopenia 
(hemoglobin of 5.8 mg/dl, thrombocytopenia of 13 g/l and neutro-
penia of 0.33 g/l) developed. Zidovudine (300 mg bid), lamivudine 
(150 mg bid), nelfinavir (1,250 mg bid) and toxoplasmosis mainte-
nance therapy (pyrimethamine/sulfamethoxazole) were stopped 
because of their potential contribution to pancytopenia. Full re-
covery of the bone marrow occurred within 10 weeks. Thereafter, 
HAART was changed to stavudine (40 mg bid), abacavir (300 mg 
bid), and lopinavir/ritonavir (400/100 mg bid), which are less likely 
to cause myelosuppression. Instead of albendazole, antihelmintic 
therapy was continued with mebendazole, another benzimidazole. 
Since a pharmacokinetic interaction was suspected to have cont-
ributed to the development of severe pancytopenia, mebendazole 
Figure 1a. CD4 and CD8 cell counts from 1996 to 2003 while under 
HAART.  While HAART resulted in undetectable HIV RNA, only a mod-
est recovery of the CD4 cell count was noted over the observation 
period. The CD4 cell count was lowest during the time of pleuro-
pneumonia and interruption of HAART.  
Figure 1b. Serology markers for echinococcosis over the past 6 years. 
EGHF-ELISA is a screening test for Echinococcus granulosus and Echi-
nococcus multilocularis. Em2-ELISA (affinity purified E. multilocularis 
Em2antigen) is specific for E. multilocularis. EM II/3-10-ELISA (recom-
binant cytovillin-like protein of  EM) can be considered as a marker 
for “viability” of E. multilocularis. In this HIV-infected patient, the si-
multaneous rise of all serologic markers of AE points to the progres-
sive disease of AE and the viability of E. multilocularis.  
Figure 1c. Therapeutic drug monitoring of mebendazole in this HIV-
infected patient while co-treated with lopinavir 400 mg bid. The 
initial mebendazole dose of 50 mg was increased to 100 mg bid to 
get appropriate serum drug levels of 300 nmol/l and more. This dose, 
however, had to be adjusted to 150 mg bid because the drug levels 
dropped below 300 nmol/l over time. The actual mebendazole dose 
is still 150 mg bid.
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plasma levels were carefully monitored after the therapy was 
initiated. Initial dose requirements were 1/20 of those normally 
used to achieve therapeutic plasma concentrations (Figure 1C). 
Therapeutic mebendazole plasma levels were reached after 6 
weeks at a dose of 150 mg bid instead of the generally required 
500–1,500 mg bid. No hematological abnormalities were ob-
served. Six months later, an abdominal CT scan showed no dis-
ease progression. The patient continued to be asymptomatic.
A review of a CT scan from 1994 showed a cystic lesion of 
3 mm in diameter in the liver suggestive of AE (Figure 2A). Re-
trospective analyses of stored serum samples retrieved from the 
repositorium of the Swiss HIV Cohort Study showed negative 
serology in 1996, but from 1997 on antibodies against EM be -
came positive and showed a trend towards higher titers until 2002 
(Figure 1B). 
Discussion
We present the second published case of coinfection with 
AE and HIV. Strikingly, the course of AE in this HIV-
positive patient was asymptomatic and remained so over 8 
years. The CD4 cell count was very low during the entire 
period. Retrospectively, the first sign suggesting AE was 
a small cyst-like lesion in the abdominal CT scan in 1994. 
Serology at that time was negative, either because the pa-
tient was not yet infected or, more likely, was due to a delay 
in seroconversion upon low CD4 cell count at that time. 
Shortly after initiation of HAART, a moderate increase in 
the CD4 cell count was noted, including seroconversion and 
subsequently persisting seropositivity. Overall the course of 
AE in this HIV-positive patient, with an estimated average 
metacestode mass increase of 45 ml per year, ranged within 
standard course variabilities of AE in immunocompetent 
patients, where a voluminometrically determined range of 
4–220 ml annual size increase in non-treated AE patients 
has been reported [13]. Therefore the present findings are 
in contrast to the first report of coinfection of HIV and AE 
[5]. Thus, HIV infection alone did not seem to predispose 
to a rapid AE progression in this adult.
The main difference between the 6-year-old girl [5] 
and our patient is the humoral and cellular immune status 
at diagnosis. The girl proved to be seronegative at diagnosis 
and exhibited no response in the lymphocyte proliferation 
assay, whereas both tests were positive in our patient. This 
might be explained by the fact that at the time of diagnosis 
the girl showed an immune status with absent CD4 cells and 
thus was no longer able to react to infection, whereas our 
patient with reduced humoral and cell-mediated immunity 
was still competent to respond to the invading parasite. 
Two weeks after the initiation of albendazole, our pa-
tient developed severe pancytopenia. Suspecting additive 
myelosuppresion due to a pharmacodynamic drug interac-
tion, all drugs were stopped. After full recovery, the anti-
retroviral therapy was modified avoiding drugs with known 
bone marrow toxicity. Mebendazole instead of albendazole 
was given. Surprisingly, the patient showed adequate serum 
drug levels with minimal doses of mebendazole, 150 mg bid 
instead of the usual 500–2,000 mg tid (Figure 1C). 
Recent in vitro data in human liver microsomes indica-
ted that the major route of albendazole biotransformation is 
oxidative metabolism via cytochrome P450 3A4 (CYP3A4) 
[14]. As albendazole is not a substrate of the drug efflux 
transporter MDR1-P-glycoprotein [15], extensive intesti-
nal CYP3A4-dependent metabolism is a likely mechanism 
underlying poor oral bioavailibility of albendazole.
Protease inhibitors such as nelfinavir and ritonavir are 
strong inhibitors of CYP3A4-dependent metabolism, while 
cytochrome P450 inhibition is not described for any of the 
other drugs taken by the patient. In the case of ritonavir, 
this property is used therapeutically to increase systemic 
exposure of drugs with low oral bioavailability such as lopi-
navir, through inhibition of intestinal and hepatic first pass 
metabolism [16]. Although formal proof through measu-
rement of albendazole plasma levels is lacking, it can be 
speculated that inhibition of albendazole first pass meta-
bolism by nelfinavir has significantly increased albendazole 
plasma levels. Given the dose-dependent myelosuppres-
sive properties of albendazole, this pharmacokinetic inter-
action might be even more important for the development 
of pancytopenia than the additive myelosuppressive effect 
of the other drugs. 
A significant pharmacokinetic interaction between 
benzimidazoles and HIV protease inhibitors is further sup-
ported by the finding of a significantly reduced dose re-
quirement of mebendazole, which replaced albendazole in 
the latter course of the patient’s history. Mebendazole is a 
structural analogue of albendazole. Similar to albendazole, 
mebendazole has a poor oral bioavailability and undergoes 
extensive intestinal and hepatic metabolism. Although the 
direct contribution of different CYP450 isoforms to me-
bendazole metabolism has not been studied in detail, ci-
metidine, a potent non-specific cytochrome P-450 inhibitor 
was shown to significantly increase mebendazole plasma 
levels [17]. Low oral bioavailability (2–10%) makes me-
Figure 2A. CT scan of the liver done in 1994 and 2002. A. The liver CT 
scan from 1994 shows a small cyst-like structure in liver segment 
IV with a diameter of 5 mm without calcifications. Retrospectively, 
this lesion is highly suggestive of AE. B. The liver CT scan from 2002 
reveals a hypodense lesion of 10 cm in diameter in segment IVa and 
IVb. The lesion is not well demarcated and has central calcifications.
A B
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bendazole particularly prone to drug interaction, which is 
in line with an initial dose requirement of 1/20 of the nor-
mal therapeutic dose under concomitant treatment with ri-
tonavir/lopinavir. As ritonavir is known to induce CYP3A4 
under long-term therapy, mebendazole dose requirements 
increased steadily, to finally reach a dose of 1/13 of that 
usually given.  
In summary, we describe the case of an HIV-infected 
patient presenting with a long asymptomatic course of 
AE despite his being severely immunocompromised. In 
reviewing the favorable course of this disease, it is note-
worthy that the patient exhibited both a positive serology 
and cellular responsiveness to parasite antigens at the time 
of diagnosis. Co-medication of protease inhibitors with me-
bendazole in this patient revealed a serious drug interac-
tion of this drug with nelfinavir and ritonavir, which has not 
been described so far. Since we did not measure albenda-
zole serum concentrations, there is no proof that the same 
drug interaction applies for all benzimidazoles. Although 
the mechanisms of this interaction remain to be fully esta-
blished, physicians should be aware of this potentially life-
threatening interaction and carefully monitor albendazole 
and mebendazole plasma levels under co-medication with 
CYP3A4-inhibiting drugs such as protease inhibitors, azole 
fungicides, or macrolide antibiotics.
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